Leading specialty pharmaceutical company focused on the creation and commercialization of innovative drug delivery technologies
Raised to date
$70M
of $176.7M offered across 2 Form D filings
With a mission to enhance patient experiences associated with injectable medications, the company develops solutions that significantly improve comfort and convenience for individuals requiring regular treatment.
The company's focus on user-friendly and less invasive drug delivery systems positions it as a pioneer in improving patient compliance and overall therapeutic outcomes.
| Filed | Security | Sold of offered | Filing |
|---|---|---|---|
| May 15, 2025 | Equity | $30M/ $136.7M | Form D |
| Mar 12, 2025 | Security to be acquired | $40M/ $40M | Form D |
Auto-Injector
XYOSTED® is an auto-injector specifically designed for testosterone replacement therapy. It enables patients to self-administer their medication efficiently and comfortably, overcoming the common barriers associated with traditional injection methods.
Built for
Patients with chronic conditions requiring injectable medications
